Skip to main content
Top
Published in: Familial Cancer 4/2009

01-12-2009

Association of MUTYH and MSH6 germline mutations in colorectal cancer patients

Authors: María Dolores Giráldez, Francesc Balaguer, Trinidad Caldés, Ana Sanchez-de-Abajo, Nuria Gómez-Fernández, Clara Ruiz-Ponte, Jenifer Muñoz, Pilar Garre, Victoria Gonzalo, Leticia Moreira, Teresa Ocaña, Joan Clofent, Angel Carracedo, Montserrat Andreu, Rodrigo Jover, Xavier Llor, Antoni Castells, Sergi Castellví-Bel, Gastrointestinal Oncology Group of the Spanish Gastroenterological Association

Published in: Familial Cancer | Issue 4/2009

Login to get access

Abstract

Colorectal cancer (CRC) risk associated with germline monoallelic MUTYH mutations remains controversial, although a slightly increased risk for this disease has been suggested. MUTYH and MSH6 proteins act in cooperation during the DNA repair process. Based on this interaction, it was hypothesized that the combination of heterozygote germline mutations in both genes could result in an increased CRC risk. To further clarify the interaction between MUTYH and MSH6, we analyzed the prevalence of MSH6 mutations in a cohort of CRC patients and controls previously tested for MUTYH mutations: CRC patients with and without a monoallelic MUTYH mutation (group I, n = 26; group II, n = 50, respectively), and healthy carriers with a monoallelic MUTYH mutation (group III, n = 21). In group I, we found three patients (11.5%) with MSH6 mutations, a missense mutation (p.R635G), a change in the 3′UTR region (c.*4098A > C) and a nonsense mutation (p.Q982X). In group II and III, no mutations were detected. In CRC patients, MSH6 mutations were more frequently found in MUTYH mutation carriers than in noncarriers (11.5% vs. 0%, P = 0.037). CRC patients carrying monoallelic MUTYH mutations harbor more frequently concomitant MSH6 mutations than patients without them, thus suggesting that both genes could act cooperatively and confer together an increased CRC risk.
Literature
1.
go back to reference Slupska MM, Luther WM, Chiang JH et al (1999) Functional expression of hMUTYH, a human homolog of the Escherichia coli MutY protein. J Bacteriol 181:6210–6213PubMed Slupska MM, Luther WM, Chiang JH et al (1999) Functional expression of hMUTYH, a human homolog of the Escherichia coli MutY protein. J Bacteriol 181:6210–6213PubMed
2.
go back to reference Al-Tassan N, Eisen T, Maynard J et al (2002) Inherited variants of MUTYH associated with somatic G:C→A mutations in colorectal tumors. Nat Genet 30:227–232CrossRefPubMed Al-Tassan N, Eisen T, Maynard J et al (2002) Inherited variants of MUTYH associated with somatic G:C→A mutations in colorectal tumors. Nat Genet 30:227–232CrossRefPubMed
3.
go back to reference Van Puijenbroek M, Nielsen M, Tops CM et al (2008) Identification of patients with (atypical) MUTYH-associated polyposis by KRAS2 c.34G>T prescreening followed by MUTYH hotspot analysis in formalin-fixed paraffin-embedded tissue. Clin Cancer Res 14:139–142CrossRefPubMed Van Puijenbroek M, Nielsen M, Tops CM et al (2008) Identification of patients with (atypical) MUTYH-associated polyposis by KRAS2 c.34G>T prescreening followed by MUTYH hotspot analysis in formalin-fixed paraffin-embedded tissue. Clin Cancer Res 14:139–142CrossRefPubMed
4.
go back to reference Riegert-Johnson DL, Johnson RA, Rabe KG et al (2007) The value of MUTYH testing in patients with early onset microsatellite stable colorectal cancer referred for hereditary nonpolyposis colon cancer syndrome testing. Genet Test 11:361–365CrossRefPubMed Riegert-Johnson DL, Johnson RA, Rabe KG et al (2007) The value of MUTYH testing in patients with early onset microsatellite stable colorectal cancer referred for hereditary nonpolyposis colon cancer syndrome testing. Genet Test 11:361–365CrossRefPubMed
5.
go back to reference Jenkins MA, Croitoru ME, Monga N et al (2006) Risk of colorectal cancer in monoallelic and biallelic carriers of MUTYH mutations: a population-based case-family study. Cancer Epidemiol Biomarkers Prev 15:312–314CrossRefPubMed Jenkins MA, Croitoru ME, Monga N et al (2006) Risk of colorectal cancer in monoallelic and biallelic carriers of MUTYH mutations: a population-based case-family study. Cancer Epidemiol Biomarkers Prev 15:312–314CrossRefPubMed
6.
go back to reference Balaguer F, Castellví-Bel S, Castells A et al (2007) Identification of MYH mutation carriers in colorectal cancer: a multicentre, case-control, population-based study. Clin Gastroenterol Hepatol 5:379–387CrossRefPubMed Balaguer F, Castellví-Bel S, Castells A et al (2007) Identification of MYH mutation carriers in colorectal cancer: a multicentre, case-control, population-based study. Clin Gastroenterol Hepatol 5:379–387CrossRefPubMed
7.
go back to reference Kovtun IV, McMurray CT (2007) Crosstalk of DNA glycosylases with pathways other than base excision repair. DNA Repair (Amst) 6:517–529CrossRef Kovtun IV, McMurray CT (2007) Crosstalk of DNA glycosylases with pathways other than base excision repair. DNA Repair (Amst) 6:517–529CrossRef
8.
go back to reference Gu Y, Parker A, Wilson TM et al (2002) Human MutY homolog, a DNA glycosylase involved in base excision repair, physically and functionally interacts with mismatch repair proteins human MutS homolog 2/human MutS homolog 6. J Biol Chem 277:11135–11142CrossRefPubMed Gu Y, Parker A, Wilson TM et al (2002) Human MutY homolog, a DNA glycosylase involved in base excision repair, physically and functionally interacts with mismatch repair proteins human MutS homolog 2/human MutS homolog 6. J Biol Chem 277:11135–11142CrossRefPubMed
9.
10.
go back to reference Niessen RC, Sijmons RH, Ou J et al (2006) MUTYH and the mismatch repair system: partners in crime? Hum Genet 119:206–211CrossRefPubMed Niessen RC, Sijmons RH, Ou J et al (2006) MUTYH and the mismatch repair system: partners in crime? Hum Genet 119:206–211CrossRefPubMed
11.
go back to reference Steinke V, Rahner N, Morak M et al (2008) No association between MUTYH and MSH6 germline mutations in 64 HNPCC patients. Eur J Hum Genet 16:587–592CrossRefPubMed Steinke V, Rahner N, Morak M et al (2008) No association between MUTYH and MSH6 germline mutations in 64 HNPCC patients. Eur J Hum Genet 16:587–592CrossRefPubMed
12.
go back to reference van Puijenbroek M, Nielsen M, Reinards TH et al (2007) The natural history of a combined defect in MSH6 and MUTYH in a HNPCC family. Fam Cancer 6:43–51CrossRefPubMed van Puijenbroek M, Nielsen M, Reinards TH et al (2007) The natural history of a combined defect in MSH6 and MUTYH in a HNPCC family. Fam Cancer 6:43–51CrossRefPubMed
13.
go back to reference Kariola R, Hampel H, Frankel WL et al (2004) MSH6 missense mutations are often associated with no or low cancer susceptibility. Br J Cancer 91:1287–1292CrossRefPubMed Kariola R, Hampel H, Frankel WL et al (2004) MSH6 missense mutations are often associated with no or low cancer susceptibility. Br J Cancer 91:1287–1292CrossRefPubMed
14.
go back to reference Piñol V, Castells A, Andreu M et al (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293:1986–1994CrossRefPubMed Piñol V, Castells A, Andreu M et al (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293:1986–1994CrossRefPubMed
15.
go back to reference Sánchez de Abajo A, de la Hoya M, Tosar A et al (2005) Low prevalence of germline hMSH6 mutations in colorectal cancer families from Spain. World J Gastroenterol 11:5770–5776PubMed Sánchez de Abajo A, de la Hoya M, Tosar A et al (2005) Low prevalence of germline hMSH6 mutations in colorectal cancer families from Spain. World J Gastroenterol 11:5770–5776PubMed
16.
go back to reference Xicola RM, Llor X, Pons E et al (2007) Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst 99:244–252CrossRefPubMed Xicola RM, Llor X, Pons E et al (2007) Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst 99:244–252CrossRefPubMed
17.
go back to reference Berndt SI, Platz EA, Fallin MD et al (2007) Mismatch repair polymorphisms and the risk of colorectal cancer. Int J Cancer 120:1548–1554CrossRefPubMed Berndt SI, Platz EA, Fallin MD et al (2007) Mismatch repair polymorphisms and the risk of colorectal cancer. Int J Cancer 120:1548–1554CrossRefPubMed
18.
go back to reference Campbell PT, Curtin K, Ulrich C et al (2008) Mismatch repair polymorphisms and risk of colon cancer, tumor microsatellite instability, and interactions with lifestyle factors. Gut 58:661–667CrossRefPubMed Campbell PT, Curtin K, Ulrich C et al (2008) Mismatch repair polymorphisms and risk of colon cancer, tumor microsatellite instability, and interactions with lifestyle factors. Gut 58:661–667CrossRefPubMed
19.
go back to reference Farrington SM, Tenesa A, Barnetson R et al (2005) Germline susceptibility to colorectal cancer due to base-excision repair gene defects. Am J Hum Genet 77:112–119CrossRefPubMed Farrington SM, Tenesa A, Barnetson R et al (2005) Germline susceptibility to colorectal cancer due to base-excision repair gene defects. Am J Hum Genet 77:112–119CrossRefPubMed
20.
go back to reference Jones N, Vogt S, Nielsen M et al (2009) Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. Gastroenterology 137:489–494CrossRefPubMed Jones N, Vogt S, Nielsen M et al (2009) Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. Gastroenterology 137:489–494CrossRefPubMed
21.
go back to reference Nielsen M, Joerink-van de Beld MC, Jones N et al (2009) Analysis of MUTYH genotypes and colorectal phenotypes in patients With MUTYH-associated polyposis. Gastroenterology 136:471–476CrossRefPubMed Nielsen M, Joerink-van de Beld MC, Jones N et al (2009) Analysis of MUTYH genotypes and colorectal phenotypes in patients With MUTYH-associated polyposis. Gastroenterology 136:471–476CrossRefPubMed
22.
go back to reference Plaschke J, Engel C, Krüger S et al (2004) Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German hereditary nonpolyposis colorectal cancer consortium. J Clin Oncol 22:4486–4494CrossRefPubMed Plaschke J, Engel C, Krüger S et al (2004) Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German hereditary nonpolyposis colorectal cancer consortium. J Clin Oncol 22:4486–4494CrossRefPubMed
23.
go back to reference Berends MJ, Wu Y, Sijmons RH et al (2002) Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet 70:26–37CrossRefPubMed Berends MJ, Wu Y, Sijmons RH et al (2002) Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet 70:26–37CrossRefPubMed
25.
go back to reference Lipton L, Halford SE, Johnson V et al (2003) Carcinogenesis in MUTYH-associated polyposis follows a distinct genetic pathway. Cancer Res 63:7595–7599PubMed Lipton L, Halford SE, Johnson V et al (2003) Carcinogenesis in MUTYH-associated polyposis follows a distinct genetic pathway. Cancer Res 63:7595–7599PubMed
Metadata
Title
Association of MUTYH and MSH6 germline mutations in colorectal cancer patients
Authors
María Dolores Giráldez
Francesc Balaguer
Trinidad Caldés
Ana Sanchez-de-Abajo
Nuria Gómez-Fernández
Clara Ruiz-Ponte
Jenifer Muñoz
Pilar Garre
Victoria Gonzalo
Leticia Moreira
Teresa Ocaña
Joan Clofent
Angel Carracedo
Montserrat Andreu
Rodrigo Jover
Xavier Llor
Antoni Castells
Sergi Castellví-Bel
Gastrointestinal Oncology Group of the Spanish Gastroenterological Association
Publication date
01-12-2009
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2009
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-009-9282-4

Other articles of this Issue 4/2009

Familial Cancer 4/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine